The use of end-points other than overall survival (OS) in oncological randomised controlled trials (RCTs) can, under some conditions, reduce the cost and duration of studies. 1 However, the validity of these alternative end-points is not consistently proven in most malignancies, including multiple myeloma (MM), and therefore their widespread use is of concern. 2 Drugs approved by regulatory authorities for MM on the basis of surrogate end-points in Europe and the United States over the last 15 years include carfilzomib, ixazomib, thalidomide, lenalidomide, pomalidomide, liposomal doxorubicin, panobinostat, daratumumab, isatuximab, elotuzumab, 3 selinexor, belantamab mafodotin, ciltacabtagene autoleucel, and idecabtagene vicleucel. 4-6 Some of these agents have gone on to demonstrate an OS benefit in confirmatory registration trials. 7,8
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.